01—Abstract
Summary
Summary of the 8-K filed September 30, 2026. Cited figures are marked; the original filing is the authoritative source.
Regeneron (REGN) filed an 8-K on September 30, 2026 disclosing two governance and compensation actions.
First, effective September 24, 2026, the Compensation Committee, with approval from independent directors, granted co-founders Leonard Schleifer (CEO) and George Yancopoulos (CSO) a one-time, 100%a performance-based award of performance share units (2026 PSUs) under the 2014 Long-Term Incentive Plan. The awards replace annual long-term incentive grants for both executives through 2036, run over a 10-year performance period (2026–2035), and carry a mandatory holding period into February 2036. Payouts depend on new product filings and approvals (smaller earnout) and new product revenues (the largest earnout), with a relative TSR modifier of up to ±20% against the NASDAQ Biotechnology Index.
Hard caps are 2.7 million PSUs for the CEO and 2.9 million for the CSO, and the maximum earnout requires roughly $30 billionb in annual new-product revenue, about double Regeneron's 2025 total revenue. Second, the Company formed a New Subsidiary to explore a potential non-core business. Both executives received partially vesting equity stakes in it.
The company describes the entity as nominal in value, without significant assets, not yet operating, and possibly never pursuing the opportunity. Its financial impact appears immaterial at this stage. For investors, the key points are the alignment of the co-founders' pay with long-term pipeline and commercial delivery, and the design choices shaped by shareholder engagement, including the heavier weighting toward revenue and the succession planning requirement.
Retention risk is reduced because forfeiture applies on voluntary departure. Dilution and expense are a consideration, though the filing does not quantify the grant-date fair value or the dilutive effect of the awards.
02—Key points
Key Highlights
- Co-founders Leonard Schleifer (CEO) and George Yancopoulos (CSO) received one-time 2026 PSU awards, granted effective September 24, 2026, that replace annual LTIP grants through 2036.
- Awards cover a 10-year performance period (January 1, 2026 to December 31, 2035) and are 100% performance-based, with a mandatory holding period into February 2036.
- The largest earnout is tied to new product annual revenue, with no revenue-based PSUs earned below $10 billion; maximum payout requires about $30 billion, roughly double 2025 total revenue.
- Activity-based earnouts from filings and approvals are capped at 100,000 PSUs (CEO) and 300,000 PSUs (CSO) below $10 billion in new product revenue, and an rTSR modifier adjusts earned PSUs by up to ±20%.
- Absolute hard caps are 2,700,000 PSUs for the CEO and 2,900,000 PSUs for the CSO, with a higher CSO limit reflecting his R&D responsibilities.
- Awards require good-faith participation in CEO and CSO succession planning, with formal plans due by the fifth anniversary of the grant.
- The Company formed a majority-owned New Subsidiary, in which both executives received partially vesting equity, to explore a non-core opportunity; the entity is nominal in value and has no significant operations.
03—Questions
Frequently Asked Questions
Why are Regeneron's co-founders receiving performance share units, and what is the structure?
The Compensation Committee describes the awards as a one-time, multi-year design intended to drive long-term value creation and reflect feedback from large investors. The PSUs are fully performance-based and replace annual long-term incentive grants for the CEO and CSO through 2036.
What performance targets must be met for the awards to pay out?
Earnouts depend on filing and FDA approval of new molecular entities and eligible supplemental applications, which are activity-based and capped, and on new product annual revenues measured for fiscal 2032–2035. Revenue payouts begin at $10 billion, with 250,000 PSUs at that level and 1.8 million PSUs at $30 billion. The maximum requires a total new-product revenue of roughly $30 billion or more, plus positive absolute TSR that outperforms the NBI.
Can the executives sell the shares soon after they vest?
No. Shares delivered before December 31, 2035 remain subject to a mandatory holding period until February 2036, with exceptions for death, disability, or a change in control. Shares delivered before the end of the performance period are also subject to a 20% holdback until the relative TSR adjustment is made.
What happens if an executive leaves the company?
Voluntary departure or retirement forfeits unvested PSUs. Termination without cause or for good reason (outside a change in control) keeps the PSUs outstanding, with earnouts limited to existing and eligible new products. Board service also satisfies the continued-service requirement, and the executives have a right to be nominated to the Board while they remain CEO or CSO.
What is the New Subsidiary, and does it matter financially?
The New Subsidiary was formed to explore a potential non-core business. Regeneron controls it and it is nominal in value, with no significant assets, no operations, and uncertain prospects. Its financial impact appears immaterial for now, and the restricted stock agreements will be filed with the Q3 2026 Form 10-Q.
04—Continue